INSERM CRNCA UMR892, Nantes, France.
Exp Hematol. 2012 Oct;40(10):783-91. doi: 10.1016/j.exphem.2012.06.008. Epub 2012 Jun 19.
Histone deacetylase inhibitors are presently used in the routine clinic treatment against cancers. Recent data have established that some of these treatments have potent anti-inflammatory or immunomodulatory effects at noncytotoxic doses that might be of benefit in immuno-inflammatory disorders or post-transplantation. At least some of these effects result from the ability of histone deacetylase inhibitors to modulate the immune system. Dendritic cells are professional antigen presenting cells that play a major role in this immune system. Data summarized in this review brings some novel information on the impact of histone deacetylase inhibitors on dendritic cell functions, which may have broader implications for immunotherapeutic strategies.
组蛋白去乙酰化酶抑制剂目前被用于癌症的常规临床治疗。最近的数据表明,这些治疗中的一些在非细胞毒性剂量下具有很强的抗炎或免疫调节作用,这可能对免疫炎症性疾病或移植后有益。至少其中一些作用是由于组蛋白去乙酰化酶抑制剂调节免疫系统的能力。树突状细胞是专业的抗原提呈细胞,在免疫系统中发挥主要作用。本综述中总结的数据提供了一些关于组蛋白去乙酰化酶抑制剂对树突状细胞功能影响的新信息,这可能对免疫治疗策略具有更广泛的意义。